Issue 11/2022
Dr. V. Mikhneva1, Prof. I. Daskalova, dm, dmn1,, Dr. I. Bogomilov2,
1Clinic “Endocrinology and Metabolic Diseases”, MMA – Sofia
2 Department of Pharmacology and Toxicology, Medical University – Sofia
Metabolic syndrome (MS) characterizes a cluster of metabolic dysregulations, including insulin resistance, atherogenic dyslipidemia, central obesity, and hypertension. The pathogenesis of MS encompasses multiple genetic and acquired pathological processes that fall under the umbrella of insulin resistance and chronic low-grade inflammation. If left untreated, MS is associated with an increased risk of developing diabetes and cardiovascular disease (CVD). Given that CVD is the leading cause of morbidity and mortality worldwide, it has become important to investigate the role of MS in this context. MS is a new clinical entity that has been the subject of numerous studies over the past few decades. However, many aspects of this clinical entity are still not fully understood and many questions remain unanswered to date. In this review, we will present a different look at new potential treatment options for metabolic syndrome beyond the usual drug suspects.
Address for correspondence: Prof. Ivona Daskalova/Dr. Ivaylo Bogomilov, Endocrinology and Metabolic Diseases Clinic, Military Medical Academy – Sofia, “St. Georgi Sofiyski” No. 3, 1606 Sofia, fax: + 359 2 9225860, phone: + 359 2 9225305, GSM: + 359 895730076, e-mail: bda.bg@abv.bg /dr.bogomilov@gmail.com